

Press release 2013-02-20

WntResearch: Positive GLP pre-clinical toxicology studies on Foxy-5

WntResearch AB (WNT.ST) announces positive results from the GLP pre-clinical studies for initiation of Phase 1 clinical trial with Foxy-5. The conclusion is that FOXY-5 is well tolerated and has a favorable safety profile. These data will be part of the Clinical Trial Application to the Danish Health and Medicines Authority (DHMA), which the Company will file in the first quarter of 2013 in order to initiate Phase 1 clinical trial.

CEO Nils Brünner comments:

"We are pleased to have reached the last but very important pre-clinical milestone. These very positive results mean that we now can finalize the package for filing a Clinical Trial Application in order to initiate the planned Phase 1 clinical trial 2013."

For further information please contact:

Nils Brünner, CEO
E-mail: nbr@wntresearch.com
Telephone: +45 2614 4708

About WntResearch AB

WntResearch (WNT.ST) is a public company listed at the AktieTorget and is a research based Biotech Company spun out of Lund University, Sweden, founded in 2007. The focus and aim of WntResearch is to develop novel anti-metastatic therapies, in areas of unmet need, for the treatment of cancer patients. The company has two major drug development projects, Foxy-5 and Box-5. The lead project Foxy-5 is planned to enter phase 1 clinical trials in metastatic cancer in the beginning of 2013.